Register: Shifting Risk | Biopharma in an Age of Deregulation

ABOUT THE EVENT

Date: Thursday, October 16, 2025 2–3pm EDT
Event Location: Virtual

One of President Donald Trump’s first executive orders highlighted a top priority for the administration: for every new regulation, 10 must be repealed. In the world of biopharma, this push toward deregulation might seem like welcome news for drugmakers, which may see an easier path to market for their products. But to balance the inherent risks associated with a less regulated system, the FDA is already working to improve monitoring of adverse events, with modern AI tools at the ready to process the massive volumes of data. For sponsors, this could mean fielding more agency inquiries. For consumers, it could mean higher quality drugs.

BioSpace sits down with former FDA Chief Information Officer Vid Desai to discuss the potential advantages and pitfalls of this regulatory shift. If the agency can go from capturing just 2–5% of adverse events to 80% or more and automatically take action, healthcare stands to benefit greatly. But such a system is something biopharma companies need to prepare for. To blind proponents of deregulation, Desai issues this warning: “Be careful what you wish for.”

Vid Desai
Former Chief Information Officer | FDA
Vid Desai is a nationally recognized healthcare technology leader with more than 35 years of experience transforming digital infrastructure across regulatory agencies, pharmaceutical companies, clinical research organizations, and medical device firms. As the Chief Information Officer at the U.S. Food & Drug Administration, Vid led the agency’s $1 billion digital portfolio, driving modernization across enterprise architecture, data governance, and cybersecurity. He is the founding executive of the FDA’s Office of Digital Transformation and the first CIO to serve on its Executive Committee and report directly to the FDA Commissioner.

Vid brings deep expertise in translating regulatory requirements into scalable and secure operational frameworks. Prior to the FDA, he served as CIO for several private equity-backed medical device companies—including Vyaire Medical, Endochoice, and Lake Region Medical—where he led global ERP integrations, divestitures, and post-acquisition transformations across many global sites. He also held senior technology leadership roles at Quintiles (now IQVIA) and GlaxoSmithKline, spearheading infrastructure modernization and global systems strategy.

With a first-class degree in Computer Science from Royal Holloway, University of London, Vid complements technical rigor with strategic foresight. His cross-sector experience enables him to advise healthcare enterprises on digital innovation, regulatory alignment, and scalable tech design. As a member of multiple advisory groups and recipient of honors including Forbes CIO Next and FedHealthIT Lifetime Achievement Awards, Vid is committed to empowering healthcare organizations to build tech ecosystems that are both resilient and mission focused.
Jef Akst
Jef Akst
Managing Editor | BioSpace
Jef is the Managing Editor for BioSpace. She earned her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses and spent the first 13 years of her career at The Scientist, where she edited features and oversaw the production of the publication’s digital and print magazines. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers. She lives in Fredericksburg, Virginia, with her husband, two young kids, wild coonhound and aging cat. Her hobbies including hiking, camping, and shooting pool.

MORE EVENTS
Join PTP, AWS and Quilt Data for an insightful webinar exploring how modern data lake architectures, built on AWS, can help your organization adopt FAIR data principles—Findable, Accessible, Interoperable, and Reusable—to unlock the full potential of your scientific data.
Wednesday, September 24, 2025 1–2pm EDT
 · 
Virtual
Drug development is already complex, but in this regulatory landscape, risks lurk at every turn. Join us for a roundtable where our guests give their observations and recommendations on how to navigate uncertainty during turbulent times.
Tuesday, September 30, 2025 11am–12pm EDT
 · 
Virtual
This webinar, tailored for scientists in academia, biotech, and pharma, will explore how intelligent mRNA designs can reduce experimental workloads and improve mRNA performance and efficacy.
Wednesday, October 15, 2025 11am–12pm EDT
 · 
Virtual